Tocopherol-modified therapeutic drug compounds
Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.
1. Butanedioic acid, (2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H- 1-benzopyran-6-yl (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizinol[1,2-b]quinolin-4-yl ester.
2. Butanedioic acid, (2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R, 8R)-4,8,12-trimethyltridecyl-2H-1-benzopyran-6-yl (4S)-4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino]1,2-b]quinolin-9-yl ester.
3. Butanedioic acid, (4S)-4,11-diethyl -3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo- 1H-pyranof[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl (2R)-3,4-dihydro-2,5,7,8-tetramethyl-2[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl ester.
4. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the compound of claim 1 , wherein the compound is in an amount from about 0.005 to about 3.0 weight percent based on the total weight of the composition.
5. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the compound of claim 2 , wherein the compound is in an amount from about 0.005 to about 3.0 weight percent based on the total weight of the composition.
6. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the compound of claim 3 , wherein the compound is in an amount from about 0.005 to about 3.0 weight percent based on the total weight of the composition.
7. A method for treating a solid tumor carcinoma, comprising administering to a subject in need thereof a therapeutically effective amount of compound of claim 1 .
8. A method for treating a solid tumor carcinoma, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 2 .
9. A method for treating a solid tumor carcinoma, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 3 .
10. A method for treating a solid tumor carcinoma, comprising administering to a subject in need thereof an emulsion comprising:
(a) an oil phase comprising
(i) the compound of claim 1 and
(ii) a lipophilic medium; and
(b) an aqueous phase.
11. A method for treating a solid tumor carcinoma, comprising administering to a subject in need thereof an emulsion comprising:
(a) an oil phase comprising
(i) the compound of claim 2 ; and
(ii) a lipophilic medium; and
(b) an aqueous phase.
12. A method for treating a solid tumor carcinoma, comprising administering to a subject in need thereof an emulsion comprising:
(a) an oil phase comprising
(i) the compound of claim 3 ; and
(ii) a lipophilic medium; and
(b) an aqueous phase.
13. The method of any of claims 7 – 12 , wherein the solid tumor carcinoma is selected from breast, ovarian, pancreatic, colon, colorectal, non-small cell lung, and bladder carcinomas.
14. The method of any of claims 10 – 12 , wherein the lipophilic medium comprises a tocopherol.